Terms: = Lung cancer AND BUB1B, BUBR1, 701, ENSG00000156970, SSK1, BUB1beta, MAD3L, hBUBR1, Bub1A, O60566 AND Treatment
88 results:
1. Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
Beckermann KE; Asnis-Alibozek AG; Atkins MB; Escudier B; Hutson TE; Kasturi V; McDermott DF; Pal SK; Porta C; Rini BI; Verzoni E
Oncologist; 2024 Mar; 29(3):254-262. PubMed ID: 38262444
[TBL] [Abstract] [Full Text] [Related]
2. Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell lung cancer: A Phase 3 Randomized Clinical Trial.
Shiraishi Y; Kishimoto J; Sugawara S; Mizutani H; Daga H; Azuma K; Matsumoto H; Hataji O; Nishino K; Mori M; Shukuya T; Saito H; Tachihara M; Hayashi H; Tsuya A; Wakuda K; Yanagitani N; Sakamoto T; Miura S; Hata A; Okada M; Kozuki T; Sato Y; Harada T; Takayama K; Yamamoto N; Nakagawa K; Okamoto I
JAMA Oncol; 2024 Mar; 10(3):315-324. PubMed ID: 38127362
[TBL] [Abstract] [Full Text] [Related]
3. Circulating miR-10b, soluble urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 as predictors of non-small cell lung cancer progression and treatment response.
Setiawan L; Setiabudy R; Kresno SB; Sutandyo N; Syahruddin E; Jovianti F; Nadliroh S; Mubarika S; Setiabudy R; Siregar NC
Cancer Biomark; 2024; 39(2):137-153. PubMed ID: 38073374
[TBL] [Abstract] [Full Text] [Related]
4. Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance.
Ridker PM; Lei L; Louie MJ; Haddad T; Nicholls SJ; Lincoff AM; Libby P; Nissen SE;
Circulation; 2024 Jan; 149(1):28-35. PubMed ID: 37929602
[TBL] [Abstract] [Full Text] [Related]
5. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.
Borghaei H; de Marinis F; Dumoulin D; Reynolds C; Theelen WSME; Percent I; Gutierrez Calderon V; Johnson ML; Madroszyk-Flandin A; Garon EB; He K; Planchard D; Reck M; Popat S; Herbst RS; Leal TA; Shazer RL; Yan X; Harrigan R; Peters S;
Ann Oncol; 2024 Jan; 35(1):66-76. PubMed ID: 37866811
[TBL] [Abstract] [Full Text] [Related]
6. A predictive scoring model to select suitable patients for surgery on primary tumor in metastatic esophageal cancer.
Wei L; Xu J; Hu X; Xie Y; Lyu G
Cancer Rep (Hoboken); 2023 Dec; 6(12):e1898. PubMed ID: 37702247
[TBL] [Abstract] [Full Text] [Related]
7. Multicenter Phase 1b/2a Clinical Trial of Radioprotectant BIO 300 Oral Suspension for Patients With Non-Small Cell lung cancer Receiving Concurrent Chemoradiotherapy.
Simone CB; Serebrenik AA; Gore EM; Mohindra P; Brown SL; Wang D; Chetty IJ; Vujaskovic Z; Menon S; Thompson J; Fine G; Kaytor MD; Movsas B
Int J Radiat Oncol Biol Phys; 2024 Feb; 118(2):404-414. PubMed ID: 37652301
[TBL] [Abstract] [Full Text] [Related]
8. Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer.
Ogusu S; Harutani Y; Tozuka T; Saito R; Koyama J; Sakamoto H; Sonoda T; Tsuchiya-Kawano Y; Oba T; Kudo K; Gyotoku H; Nakatomi K; Ariyasu R
Cancer Immunol Immunother; 2023 Nov; 72(11):3765-3772. PubMed ID: 37638979
[TBL] [Abstract] [Full Text] [Related]
9. Complete thoracoscopic lobectomy versus hybrid video-assisted thoracoscopic lobectomy for non-small cell lung cancer.
Fujita T; Koyanagi A; Kishimoto K
Gen Thorac Cardiovasc Surg; 2024 Jan; 72(1):31-40. PubMed ID: 37311943
[TBL] [Abstract] [Full Text] [Related]
10. Clinical model of pulmonary metastasis in patients with osteosarcoma: A new multiple machine learning-based risk prediction.
Su Z; Huang F; Yin C; Yu Y; Yu C
J Orthop Surg (Hong Kong); 2023; 31(2):10225536231177102. PubMed ID: 37288764
[TBL] [Abstract] [Full Text] [Related]
11. Artificial intelligence-quantified tumour-lymphocyte spatial interaction predicts disease-free survival in resected lung adenocarcinoma: A graph-based, multicentre study.
Feng Z; Lin H; Liu Z; Yan L; Wang Y; Li B; Liu E; Han C; Shi Z; Lu C; Liu Z; Pang C; Li Z; Cui Y; Pan X; Chen X
Comput Methods Programs Biomed; 2023 Aug; 238():107617. PubMed ID: 37235970
[TBL] [Abstract] [Full Text] [Related]
12. Epidemiological and clinical characteristics of synchronous lung metastasis in major salivary gland mucoepidermoid carcinoma.
Li Y; Hu C
Eur Arch Otorhinolaryngol; 2023 Aug; 280(8):3835-3841. PubMed ID: 37100896
[TBL] [Abstract] [Full Text] [Related]
13. Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial.
Huang DT; McCreary EK; Bariola JR; Minnier TE; Wadas RJ; Shovel JA; Albin D; Marroquin OC; Kip KE; Collins K; Schmidhofer M; Wisniewski MK; Nace DA; Sullivan C; Axe M; Meyers R; Weissman A; Garrard W; Peck-Palmer OM; Wells A; Bart RD; Yang A; Berry LR; Berry S; Crawford AM; McGlothlin A; Khadem T; Linstrum K; Montgomery SK; Ricketts D; Kennedy JN; Pidro CJ; Nakayama A; Zapf RL; Kip PL; Haidar G; Snyder GM; McVerry BJ; Yealy DM; Angus DC; Seymour CW
JAMA Netw Open; 2022 Jul; 5(7):e2220957. PubMed ID: 35834252
[TBL] [Abstract] [Full Text] [Related]
14. The Persistence of Poverty and its Impact on cancer Diagnosis, treatment and Survival.
Papageorge MV; Woods AP; de Geus SWL; Ng SC; McAneny D; Tseng JF; Kenzik KM; Sachs TE
Ann Surg; 2023 Jun; 277(6):995-1001. PubMed ID: 35796386
[TBL] [Abstract] [Full Text] [Related]
15. Cost-effectiveness analysis of pegfilgrastim in patients with non-small cell lung cancer receiving ramucirumab plus docetaxel in Japan.
Kondo Y; Tachi T; Sakakibara T; Kato J; Kato A; Mizuno T; Miyake Y; Teramachi H
Support Care Cancer; 2022 Aug; 30(8):6775-6783. PubMed ID: 35524869
[TBL] [Abstract] [Full Text] [Related]
16. Prognosis of resected non-small cell lung cancer with pleural plaques on intrathoracic findings.
Kagimoto A; Mimura T; Kamigaichi A; Yamashita Y
BMC Cancer; 2022 Apr; 22(1):469. PubMed ID: 35484615
[TBL] [Abstract] [Full Text] [Related]
17. Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell lung cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial.
Majem M; Goldman JW; John T; Grohe C; Laktionov K; Kim SW; Kato T; Vu HV; Lu S; Li S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Atagi S; Zeng L; Kulkarni D; Medic N; Tsuboi M; Herbst RS; Wu YL
Clin Cancer Res; 2022 Jun; 28(11):2286-2296. PubMed ID: 35012927
[TBL] [Abstract] [Full Text] [Related]
18. Bioinformatics study on genes related to a high-risk postoperative recurrence of lung adenocarcinoma.
Lin X; Zhou M; Xu Z; Chen Y; Lin F
Sci Prog; 2021; 104(3):368504211018053. PubMed ID: 34304612
[TBL] [Abstract] [Full Text] [Related]
19. Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis.
Chen J; Wang J; Xu H
Medicine (Baltimore); 2021 Apr; 100(15):e25180. PubMed ID: 33847617
[TBL] [Abstract] [Full Text] [Related]
20. Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis.
Kok PS; Lee K; Lord S; Yang JC; Rosell R; Goto K; John T; Wu YL; Mok TSK; Lee CK
Lung Cancer; 2021 Apr; 154():113-117. PubMed ID: 33647577
[TBL] [Abstract] [Full Text] [Related]
[Next]
